Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia

Boehringer Ingelheim

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Drug: ALNA®

Study type: Observational

Funder types: Industry

Identifiers

NCT02244268

527.20

Details and patient eligibility

About

The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved occupational performance of the patients being still employed. Additionally to obtain relevant information for the 5-year report of experience with this product according to the requirements in § 49, para 6 of the German Medicines Act.

Enrollment: 3,629 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients suffering from symptomatic benign prostatic hyperplasia (BPH) symptoms and receiving ALNA® treatment are to be included in the observation according to the prescribing information

Exclusion criteria

No exclusion criteria is defined, prescribing information is to be considered

Trial design

3,629 participants in 1 patient group

Patient with symptomatic of benign prostatic hyperplasia

Treatment:

Drug: ALNA®